Positron emission tomography: Progress in medical imaging;La tomographie par emission de positons: Une avancee en imagerie medicale

Feuillets de Radiologie

Volumn 40, Issue 3, 2000, Pages 210-218

  Vaylet, F ^a   De Dreuille, O ^b   Foehrenbach, H ^b   Guigay, J ^a   Maszelin, P ^b   Dot, J M ^a   Grassin, F ^a   Margery, J ^a   Gaillard, J F ^b   L'her, P ^a  

^a Service des Maladies Respiratoires   (France)

^b Serv de Med Nucleaire   (France)

Author keywords

Cancer; Chemotherapy; Extension; Lungs; Nodule; PET; Positron emission tomography

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER LOCALIZATION; DIAGNOSTIC IMAGING; HUMAN; IMAGING SYSTEM; LUNG CANCER; LUNG NODULE; POSITRON EMISSION TOMOGRAPHY; REVIEW;

EID: 6744245567     PISSN: 01819801     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Bendriem B. Les détecteurs de positions. Caméra PET-Caméra PET-SPECT. Revue de l'ACOMEN, 1998; 4: 34-40.
2. Weber WA, Neverve J, Sklarek J, Ziegler SI, Bartenstein P, King B, Treumann T, Enterrottacher A, Krapf M, Haussinger KE, Lichte H, Prauer HW, Thetter O, Schwaiger M. Imaging of lung cancer with fluorine - 18 fluorodeoxyglucose: comparison of a dual-head camera in coincidence mode with a full-ring position emission tomography system. Eur J Nucl Med 1999; 26: 388-95.
3. Warburg O, Wind F, Neglers E. On the metabolism of the tumors in the body. In: Warburg O, ed, Metabolism of tumors, London, Constable, 1930, pp. 254-270.
4. Vuillez JP. Métabolisme glucidique des cellules tumorales : conséquences pour l'utilisation de radio-pharmaceutiques analogues du glucose. Med Nucl IFM 1998 ; 22 : 9-29.
5. Rigo P, Paulus P, Jerusalem G, Bury T, Deneufbourg JM, Depas G, Benoit T, Larock MP, Foidart J. Indications cliniques de la tomographie par émission de positions au 18FDG en oncologie. Expérience préliminaire et revue de la littérature. Med Nucl IFM 1995 ; 19 : 73-89.
6. Vaylet F, Foehrenbach H, de Dreuille O, Maszelin P, Merlet P, Bendriem B, L'Her P, Gaillard J-F. Fluoro-deoxy-glucose et cancer broncho-pulmonaire. Les premiers résultats français en caméra à positions. Rev Pneumol Clin 1998 ; 54 : 187-95.
7. Vaylet F, Maszelin P, deDreuille O, Guigay J, Foehrenbach H, Le Vagueresse R, Grassin F, Dot JM, L'Her P, Syrota A, Gaillard JF. Résultats de la première étude française en caméra dédiée de la tomographie par émission de positions au 18Fluoro-désoxyglucose en oncologie broncho-pulmonaire. Communication devant la Société Médicale des Hôpitaux de Paris le 19.11.1999.
8. Strauss LG. Fluorine 18 désoxyglucose and false-positive results: a major problem in the diagnosis of oncological patients. Eur J Nucl Med. 1996; 23: 1409-15.
9. Dewan NA, Shehan CJ, Reeb RD, Gobar LS, Scott WJ, Ryschon K. Likelihood of malignancy in a solitary pulmonary nodule. Comparison of a bayesian analysis and results of FDG-PET scan. Chest 1997; 112: 416-422.
10. Bury T, Paulus P, Dowlati A, Corhay JL, Rigo P, Rademecker MF. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax, 1997; 52: 187-89.
11. Benard F, Sterman D, Smith RJ, Kaiser LR, Albeldz SM, Alavi A. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxysclucose positron emission tomography. Chest, 1998; 114: 713-22.
12. Gould MK, Owens DK. Position emission tomography for mediastinal staging in non small cell lung cancer: a meta-analysis. Proceedings. ASCO, 1999, Abs. A256.
13. Lowe VJ, Naunheim KS. Positron Emission tomography in lung cancer. Ann Thorac Surg 1998 ; 65: 1821-9.
14. Vaylet F. Abord diagnostique des adénopathies médiastinales : intérêt de la Tomographie par émission de positons. Communication lors de la Journée de pathologie thoracique du Val de Grâce, le 6,11,1998.
15. Erasmus JJ, Patz EF, McAdams HP, Murray JG, Herndon J, Coleman RE, Goodman PC. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18FDG positron emission tomography. Am J Roentgenol 1997, 168, 1357-60
16. Porte HL, Ernst OJ, Métois D, Lemaitre LG, Wurtz AJ. Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non small cell lung cancer? Eur J Cardiothor Surg 1999; 15, 567.
17. Ahuja V, Coleman RE, Herndon J, Patz EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non small lung carcinoma. Cancer 1998; 83: 918-24.
18. Vansteekiste J, Stroobants P, Dupont P, and coll. Pronostic Importance of Fluorodeoxyglucose-Uptake on PET-Scan in Non-Small Cell Lung Cancer: An Analysis of 125 Cases. Proceedings ASCO 1999, Abs. 1791.
19. Sugawara Y, Quint LE, Russo JE, and coll. FDG Uptake in non small cell lung cancer does not independently predict patient survival. J Nucl Med 1999; 40: 246.
20. Frank A, Lefkowitz D, Jaeger S, Gobar L, Sunderland J, Gupta N, and coll. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings. Int J Radiation Oncology Biol Phys 1995; 32: 1495-512.
21. Hebert ME, Lowe VJ, Hoffman JM, Patz EF, Anscher MS. Positron Emission Tomography in the Pretreatment Evaluation and Follow-Up of Non-Small Cell Lung Cancer Patients Treated with Radiotherapy: Preliminary Findings. Am J Clin Oncol 1996; 19: 416-21.
22. Bury T, Salem T, Vandenheede M, Cataldo D, Rigo P. Intérêt de la Tomographie par émission de positrons (TEP) au 18-fluorodeoxyglucose (18FDG) dans le suivi thérapeutique du cancer pulmonaire non petites cellules (CPNPC). Rev Mal Respir 1999 ; 16 : 1S46.
23. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991; 32: 623-48.
24. Wahl RL, Zasadny K, Helvic M and coll. Metabolic monitoring of breast cancer chemohormontherapy using positron emission tomography. Initial evaluation. J Clin Oncol 1993; 11: 2101-11.
25. Ichiya Y, Saski M, Yoshida T, Omagari J, Akashi Y, Kawashima A, Fukumura T, Masuda K. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med 1996; 10: 193-200.
26. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of the non small cell lung carcinoma. J Nucl Med 1996; 37: 1428-36.
27. Weber W, Bülow H, Römer W, Präuer H. Gambhir SS, Schwaiger M. FDG PET in solitary pulmonary nodules: a german cost-effectiveness analysis. J Nucl Med 1997; 38: 245P.
28. Landoni C., Gianolli L, Lucignani G, Magnani P, Savi A, Travaini L. Fazio F. Comparison of dual-head coincidence imaging PET versus conventional ring PET in tumors patients. Eur J Nucl Med 1999; 25: OS-379.
29. Eary JF. Nuclear medicine in cancer diagnosis. Lancet 1999; 354: 853-7.